Name: Aspirin
Brand: Selleck Chemicals
SKU: S3017
Rating: 5 (28 reviews)

Saltar a

Control de calidad

Lote: Pureza: 99.99%

99.99

Dianas relacionadas	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Otros COX Inhibidores	NS-398 (NS398) Paeoniflorin (NSC 178886) Lumiracoxib Xanthohumol Bufexamac Nimesulide Ginsenoside Rd Pranoprofen Phenacetin Tolfenamic Acid

Cultivo celular, tratamiento y concentración de trabajo

Líneas celulares	Tipo de ensayo	Concentración	Tiempo de incubación	Descripción de la actividad	PMID
AGS	Function assay	15 to 60 umol/L after	12 hrs	Inhibition of Escherichia coli-stimulated IL-8 production in human AGS cells at 15 to 60 umol/L after 12 hrs by ELISA	20153183
microglia cells	Antineuroinflammatory assay		15 mins	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge, IC50=3.12μM	22153874
HCT116	Function assay	1 mM	6 hrs	Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay	22154834
SKBR3	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human SKBR3 cells at 300 uM after 48 hrs by alamar blue assay	22494617
PANC1	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human PANC1 cells at 300 uM after 48 hrs by alamar blue assay	22494617
PC3	Growth inhibition assay	300 uM	48 hrs	Growth inhibition of human PC3 cells at 300 uM after 48 hrs by alamar blue assay	22494617
MDA-MB-231	Function assay	100 uM	30 mins	Irreversible inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay	23651359
THP1	Function assay	100 uM	30 mins	Irreversible inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay	23651359
HCT116	Cytotoxicity assay		48 hrs	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs MTT assay	26750401
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-6 in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of TNF-alpha in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by E	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring reduction in MDA levels at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in SOD activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in catalase activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of TNF-alpha in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-1beta in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as reduction in MDA levels at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by spectrophotometry	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress in rat H9c2 cells assessed as antioxidant activity by measuring increase in SOD activity at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by spec	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-6 in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by ELISA	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced oxidative stress mediated inflammation in rat H9c2 cells assessed as suppression of IL-1beta in supernatant at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs in presence of leonurine by EL	27575471
H9c2	Cardioprotective assay	1 uM	8 hrs	Cardioprotective activity against hypoxia-induced cytotoxicity in rat H9c2 cells assessed as increase in cell viability at 1 uM preincubated for 8 hrs followed by H2O2 addition for 2 hrs by MTT assay	27575471
RAW264.7	Antiinflammatory assay			Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method, IC50=43.2μM	28561586
stem cells	Function assay	100 uM	5 days	Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in adiponectin production at 100 uM measured on day 5 in presence of IDX by ELISA	29398443
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
peritoneal cells	Function assay		5 hrs	Inhibition of LPS-induced PGE2 production in C57BL6 mouse peritoneal cells measured at 5 hrs time interval by ELISA, IC50=4.08μM	30006172
HCT8	Antiproliferative assay		72 hrs	Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay, IC50=15.6μM	30037494
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as accumulation at G0/G1 phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as accumulation at S phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
RPMI8226	Cell cycle assay	1.7 uM	48 hrs	Cell cycle arrest in human RPMI8226 cells assessed as reduction in accumulation at G2/M phase at 1.7 uM in presence of bortezomib after 48 hrs by propidium iodide/RNase staining based flow cytometric method relative to bortezomib	30590258
HaCaT	Antipyretic assay	100 uM	2 hrs	Antipyretic activity in human HaCaT cells assessed as inhibition of TNFalpha-induced PGE2 production at 100 uM pre-incubated for 2 hrs before TNFalpha stimulation for 24 hrs by ELISA	31393125
OVCAR5	Function assay	300 uM to 1 mM	72 hrs	Inhibition of NAPRT in human OVCAR5 cells assessed as potentiation of NAMPT inhibitor FK866-induced cytotoxicity by measuring reduction in cell viability at 300 uM to 1 mM incubated for 72 hrs by SRB assay	ChEMBL
CCRF-CEM	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human CCRF-CEM cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
Jurkat	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Jurkat cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further i	ChEMBL
ML2	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human ML2 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incu	ChEMBL
NOMO	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NOMO cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
NB4	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NB4 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further incu	ChEMBL
NAMALWA	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human NAMALWA cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
Daudi	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Daudi cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further in	ChEMBL
Raji	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human Raji cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
ARH77	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human ARH77 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further in	ChEMBL
RPMI8226	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human RPMI8226 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further	ChEMBL
U266	Function assay	3.5 mM	48 hrs	Inhibition of NAPRT in human U266 cells assessed as potentiation of NAMPT inhibitor FK866-induced apoptosis by measuring reduction in cell viability at 3.5 mM prer-incubated with IC50 level of FK866 for 48 hrs followed by compound addition and further inc	ChEMBL
NAMALWA	Function assay	35 mg/kg	45 days	Potentiation of NAMPT inhibitor 10 mg/kg, ip bid FK866-induced antitumor activity in human NAMALWA cells xenografted in SCID mouse assessed as increase in mouse survival at 35 mg/kg, ip bid up to 45 days	ChEMBL
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad

Peso molecular	180.16	Fórmula	C₉H₈O₄	Almacenamiento (Desde la fecha de recepción)	3 años-20°Cpolvo
Nº CAS	50-78-2	Descargar SDF		Almacenamiento de soluciones madre	1 año-80°Cen disolvente 1 mes-20°Cen disolvente
Sinónimos	NSC 27223, Acetylsalicylic acid, ASA			Smiles	CC(=O)OC1=CC=CC=C1C(=O)O

Solubilidad

In vitro
Lote:

DMSO : 36 mg/mL (199.82 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Ethanol : 36 mg/mL

Water : Insoluble

Calculadora de Molaridad

Masa	Concentración	Volumen	Peso molecular
=	×	×

Calculadora de Dilución Calculadora de Peso Molecular

In vivo Lote:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

Dosis: mg/kg Peso promedio de los animales: g Volumen de dosificación por animal:μL Número de animales:

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH₂O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción

Targets/IC₅₀/Ki	COX2 COX1
In vitro	Aspirin inhibe la activación de NF-kappa B, lo que previene la degradación del inhibidor de NF-kappa B, I kappa B, y por lo tanto NF-kappa B se retiene en el citosol. Este compuesto también inhibe la transcripción dependiente de NF-kappa B del potenciador Ig kappa y de la repetición terminal larga (LTR) del virus de la inmunodeficiencia humana (VIH) en células T transfectadas. Su acción y la del salicilato están mediadas en parte por su inhibición específica de IKK-beta, previniendo así la activación por NF-kappaB de genes implicados en la patogénesis de la respuesta inflamatoria. Este producto químico es protector contra la neurotoxicidad provocada por el aminoácido excitatorio glutamato en cultivos neuronales primarios de rata y rebanadas de hipocampo. Desencadena la biosíntesis transcelular de una clase de eicosanoides previamente no reconocida durante las co-incubaciones de células endoteliales de vena umbilical humana (HUVEC) y neutrófilos [leucocitos polimorfonucleares (PMN)]. Este agente evoca una clase única de eicosanoides formados por interacciones de PGHS-2 acetilada y 5-lipoxigenasa. Su tratamiento inhibe la fosforilación de IRS-1 en Ser307, así como la fosforilación de JNK, c-Jun y la degradación de IkappaBalpha en células 3T3-L1 y Hep G2 tratadas con factor de necrosis tumoral (TNF)-alpha. Este tratamiento inhibe la fosforilación de Akt y del objetivo de rapamicina en mamíferos (pero no de la quinasa regulada por señales extracelulares o PKCzeta) en respuesta a TNF-alpha. Rescata la captación de glucosa inducida por insulina en adipocitos 3T3-L1 pretratados con TNF-alpha.
Referencias	[1] https://pubmed.ncbi.nlm.nih.gov/8052854/ [2] https://pubmed.ncbi.nlm.nih.gov/9817203/ [3] https://pubmed.ncbi.nlm.nih.gov/8910280/ [4] https://pubmed.ncbi.nlm.nih.gov/7568157/ [5] https://pubmed.ncbi.nlm.nih.gov/12714600/

Aplicaciones

Métodos	Biomarcadores	Imágenes	PMID
Western blot	MCL-1 p-AKT / AKT / p-ERK / ERK p-AMPKα / AMPKα / p-ACC / ACC SHH / SMO / GLI1 / Bcl-2 / Foxm1		26918349
Growth inhibition assay	Cell proliferation Cell viability		28446712

Información del ensayo clínico

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT	Reclutamiento	Condiciones	Patrocinador/Colaboradores	Fecha de inicio	Fases
NCT05960864	Not yet recruiting	Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)\|Non-radiographic Axial Spondyloarthritis (Nr-axSpA)\|Axial Psoriatic Arthritis (axPsA)\|Acute Anterior Uveitis (AAU)\|Crohn Disease (CD)\|Ulcerative Colitis (UC)\|Reactive Arthritis (ReA)	Southwest Hospital China	September 2024	--
NCT05868525	Recruiting	Blunt Cerebrovascular Injury	Loma Linda University	July 2024	Phase 4
NCT06197009	Not yet recruiting	Axial Spondyloarthritis	Sinocelltech Ltd.	July 1 2024	Phase 2
NCT06378398	Not yet recruiting	Colorectal Neoplasia	University of Michigan Rogel Cancer Center\|National Cancer Institute (NCI)	May 2024	Early Phase 1

Soporte técnico

Instrucciones de manipulación

Tel: +1-832-582-8158 Ext:3

Si tiene alguna otra consulta, por favor deje un mensaje.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Aspirin COX inhibidor

Estructura química

Peso molecular: 180.16